Acadia Pharmaceuticals (ACAD) PT Raised to $20 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $20.47 --0%
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 4
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 5 | Down: 13 | New: 4
Join SI Premium – FREE
Morgan Stanley analyst Jeffrey Hung raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $20.00 (from $19.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Ambit Capital Upgrades GE Vernova T&D India (GVTD:IN) to Buy (1)
- Match Group (MTCH) PT Raised to $50 at Susquehanna
- Hinge Health Inc (HNGE) PT Raised to $135 at Needham
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
